IP Library Granted Patent US 11,730,619
Granted Patent B2
US 11,730,619 · App. 17/209,545 · Granted Aug 22, 2023

Systems and methods for determining failure of intragastric devices

Inventors: Mark C. Brister (Encinitas, CA); Neil R. Drake (San Diego, CA); Antonio C. Llevares (Chula Vista, CA); Sheldon Nelson (Vista, CA); Daniel J Proctor (San Diego, CA); Andrew P. Rasdal (San Diego, CA); Keoni John Sundseth (Carlsbad, CA); Amy D.L. VandenBerg (San Diego, CA); Betty Wong (San Diego, CA)
Assignee: RESHAPE LIFESCIENCES INC.
A61F5/003A61B5/4851A61B5/6871A61F5/0036A61F5/0089A61M31/005A61B5/1032A61B5/207A61M2210/1053
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,619
App. No.
17/209,545
Granted
Aug 22, 2023
Kind
B2
Abstract

Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided.

Claims (25)

1. An intragastric volume-occupying device, comprising:

an intragastric balloon having a wall and a lumen; and

a paste or solution of methylene blue dotted or printed onto at least a portion of an interior of the wall of the instragastric balloon, wherein the methylene blue is configured to indicate a failure of the intragastric volume-occupying device by being reduced to leukomethylene blue upon exposure to gastric fluids, so as to yield a discolored urine as an indicator of failure of the intragastric volume-occupying device.

2. The intragastric volume-occupying device of claim 1 , wherein the failure is a spontaneous deflation of the intragastric balloon.

3. The intragastric volume-occupying device of claim 1 , wherein the failure is a leakage of a fill fluid contained within the intragastric balloon.

4. The intragastric volume-occupying device of claim 1 , wherein the fill fluid is SF 6 .

5. The intragastric volume-occupying device of claim 1 , wherein the fill fluid is a combination of nitrogen and SF 6 .

6. The intragastric volume-occupying device of claim 1 , wherein the device comprises 10 mg to 60 mg of methylene blue.

7. The intragastric volume-occupying device of claim 1 , further comprising a red emission dye in combination with the methylene blue, wherein the combination is dotted or printed onto at least a portion of the interior of the wall of the intragastric balloon, and wherein the combination is configured to indicate a failure of the intragastric volume-occupying device upon exposure to gastric fluids, so as to yield a purple urine as an indicator of failure of the intragastric volume-occupying device.

8. The intragastric volume-occupying device of claim 7 , wherein the red emission dye is betalain.

9. The intragastric volume-occupying device of claim 1 , wherein the paste or solution of methylene blue is dotted or printed onto a portion of the interior of the wall of the intragastric balloon near a valve of the intragastric balloon.

10. The intragastric volume-occupying device of claim 1 , wherein the intragastric balloon further comprises one or more dissolvable or water-soluble coatings applied over the paste or solution of methylene blue dotted or printed onto the at least a portion of the interior of the wall of the intragastric balloon.

11. The intragastric volume-occupying device of claim 10 , wherein upon failure of the intragastric balloon, exposure of the one or more dissolvable or water-soluble coatings to gastric fluids exposes the methylene blue to the gastric fluids.

12. A method for detecting a failure of an intragastric volume-occupying device, the method comprising:

introducing, into a stomach of a patient, an intragastric volume-occupying device comprising an intragastric balloon having a wall, a lumen, and a paste or solution of methylene blue dotted or printed onto at least a portion of an interior of the wall of the intragastric balloon;

introducing an initial fill fluid into the lumen of the intragastric balloon to inflate the intragastric balloon; and

exposing the inflated intragastric balloon to the in vivo intragastric environment until a failure of the intragastric balloon occurs, whereby the methylene blue is exposed to gastric fluids and is reduced to leukomethylene blue, so as to yield a discolored urine as an indicator of failure of the intragastric volume-occupying device.

13. The method of claim 12 , wherein the failure is a spontaneous deflation of the intragastric balloon or a leakage of the fill fluid contained within the intragastric balloon.

14. The method of claim 12 , wherein the fill fluid is SF 6 .

15. The method of claim 12 , wherein the fill fluid is a combination of nitrogen and SF 6 .

16. The method of claim 12 , wherein the methylene blue is present in a combination with a red emission dye, wherein the combination is configured to indicate a failure of the intragastric volume-occupying device upon exposure to gastric fluids, so as to yield a purple urine as an indicator of failure of the intragastric volume-occupying device.

17. The method of claim 12 , wherein the device comprises 10 mg to 60 mg of methylene blue.

18. The method of claim 12 , wherein the paste or solution of methylene blue is dotted or printed onto a portion of the interior of the wall of the intragastric balloon near a valve of the intragastric balloon.

19. The method of claim 12 , wherein the intragastric balloon further comprises one or more dissolvable or water-soluble coatings applied over the paste or solution of methylene blue dotted or printed onto the at least a portion of the interior of the wall of the intragastric balloon.

20. The method of claim 19 , wherein upon a failure of the intragastric balloon, exposure of the one or more dissolvable or water-soluble coatings to gastric fluids exposes the methylene blue to the gastric fluids.

Assignments (2)
SECURITY INTEREST Recorded Oct 24, 2024
From: RESHAPE LIFESCIENCES INC.
To: ASCENT PARTNERS FUND LLC
Reel/Frame 070166/0882 →
CHANGE OF NAME Recorded Oct 6, 2021
From: OBALON THERAPEUTICS, INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 057726/0716 →
Continuity (4)
Continuation 15097072 · Apr 12, 2016
Continuation In Part PCTUS2015062338 · Nov 24, 2015
Provisional Application 62151967 · Apr 23, 2015
Related Publication 20220039981A1 · Feb 10, 2022
Cited By (2)
US 12,440,358 US 12,514,464